The BioHeart Study: assessing patients with suspected cardiovascular disease for new disease markers and risk factors

Conditions

None listed

Brief summary

For many diseases, researchers have been able to find ‘biomarkers’ that are in the blood and that can predict whether or not someone is at risk of getting the disease. Biomarkers are naturally occurring molecules, genes, or other characteristics that help us to identify diseases and disease processes. The purpose of the research project is to use blood and tissue from people with susceptibility or resilience to cardiovascular disease (CVD), and to try and find new biomarkers that can identify risk of CVD at an early stage. In addition, we will investigate the use of biomarkers that we have already identified, and their ability to predict events and outcomes. We hope that by doing this, we will be able to: 1. Find out more about how and why CVD occurs 2. Find out more about the way that CVD progresses and affects different people 3. Find new biomarkers that will help us to work out if someone is at risk of CVD earlier 4. Find new treatments for CVD

Elijah Genetzakis, Thomas Hansen, Marie Besnier, Kristen J. Bubb, Helen M. McGuire et al. (15 authors)

European Heart Journal2023-11-01

10.1093/eurheartj/ehad655.3137

Immunoglobulin E Sensitization to Mammalian Oligosaccharide Galactose-α-1,3 (α-Gal) Is Associated With Noncalcified Plaque, Obstructive Coronary Artery Disease, and ST-Segment–Elevated Myocardial Infarction

Stephen T. Vernon, Katharine A. Kott, Thomas Hansen, Meghan Finemore, Karl Baumgart et al. (14 authors)

Arteriosclerosis Thrombosis and Vascular Biology2022-01-2038 citations

10.1161/atvbaha.121.316878

Association of Global Coagulation Profiles With Cardiovascular Risk Factors and Atherosclerosis: A Sex Disaggregated Analysis From the BioHEART‐CT Study

Katharine A. Kott, Marie‐Christine Morel‐Kopp, Stephen T. Vernon, Yuki Takagi, Belinda A. Di Bartolo et al. (10 authors)

Journal of the American Heart Association2021-10-0814 citations

10.1161/jaha.120.020604

Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study

Katharine A. Kott, Stephen T. Vernon, Thomas Hansen, Christine Yu, Kristen J. Bubb et al. (16 authors)

BMJ Open2019-09-0156 citations

10.1136/bmjopen-2018-028649

Interventions

Patients presenting with cardiac disorders or for investigation of suspected cardiac disorders are invited to participate in the BioHEART study. Biological specimens (e.g., blood) and imaging data are collected and correlated with demographic and risk factor data. Samples are analysed with the purpose of developing biomarkers for prognostic use in cardiovascular disease. Follow-up is performed at one month and then annually for the life of the study, at a minimum of 5 years.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

- Patients presenting to emergency department, cardiovascular outpatient clinics, for cardiovascular testing (e.g. CTCA) for investigation and management of suspected cardiovascular disease, or for surgery involving removal of redundant tissue containing vascular tissue. - Patients willing and able to provide informed consent

Exclusion criteria

- Patients highly dependent on medical care and unable to provide informed consent - Patients unwilling or unable to participate in on-going follow-up - Patients unwilling or unable to provide informed consent

Outcome results